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Abstract
Background: The development of a gonorrhea vaccine is challenged by the lack of correlates of protection. The
antigenically variable neisserial opacity (Opa) proteins are expressed during infection and have a semivariable (SV) and
highly conserved (4L) loop that could be targeted in a vaccine. Here we compared antibodies to linear (Ablinear) and cyclic
(Abcyclic) peptides that correspond to the SV and 4L loops and selected hypervariable (HV2) loops for surface-binding and
protective activity in vitro and in vivo.
Methods/Findings: AbSV cyclic bound a greater number of different Opa variants than AbSV linear, including variants that
differed by seven amino acids. Antibodies to the 4L peptide did not bind Opa-expressing bacteria. AbSV cyclic and AbHV2 cyclic,
but not AbSV linear or AbHV2 linear agglutinated homologous Opa variants, and AbHV2BD cyclic but not AbHV2BD linear blocked the
association of OpaB variants with human endocervical cells. Only AbHV2BD linear were bactericidal against the serum resistant
parent strain. Consistent with host restrictions in the complement cascade, the bactericidal activity of AbHV2BD linear was
increased 8-fold when rabbit complement was used. None of the antibodies was protective when administered vaginally to
mice. Antibody duration in the vagina was short-lived, however, with ,50% of the antibodies recovered 3 hrs post-
administration.
Conclusions: We conclude that an SV loop-specific cyclic peptide can be used to induce antibodies that recognize a broad
spectrum of antigenically distinct Opa variants and have agglutination abilities. HV2 loop-specific cyclic peptides elicited
antibodies with agglutination and adherence blocking abilities. The use of human complement when testing the
bactericidal activity of vaccine-induced antibodies against serum resistant gonococci is also important.
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Introduction
Gonorrhea is the second most commonly reported disease in the
United States with over 350,000 cases reported in 2006 [1] and
over 62 million estimated annual cases worldwide [2]. The
gonococcus colonizes many mucosal sites, including the cervix,
urethra, rectum, and pharynx. Ascended reproductive tract
infections are the major source of the morbidity and mortality
associated with this pathogen. Ascended infection occurs in 10–
20% of cervical infections, and can lead to pelvic inflammatory
disease (PID) and the associated complications of involuntary
infertility, ectopic pregnancy, and chronic pelvic pain [3].
Gonorrhea is also a co-factor for transmission of the human
immunodeficiency virus [4]. The public health cost of gonococcal
infections is significant; over 77 million dollars were spent in the
U.S. in the year 2000 on the diagnosis and treatment of acute
gonorrhea and post-infection sequelae in patients 15–24 years of
age [5]. The rapid emergence of antibiotic-resistant strains [6]
underscores the importance of identifying new preventive
measures against gonorrhea as illustrated by the recent removal
of fluoroquinolones from recommended treatments [7].
The development of a gonorrhea vaccine is challenged by the
lack of known correlates of protection. Repeat infections are
common even with the homologous strain [8] or serotype [9,10],
although evidence of partial immunity has been reported
[11,12]. N. gonorrhoeae does not express a capsule, which is the
target of several effective meningococcal vaccines. Therefore,
research towards a gonorrhea vaccine has focused on other
surface antigens such as outer membrane proteins. The neisserial
opacity (Opa) proteins are a family of outer membrane proteins
that mediate adherence to and invasion of tissue culture cells
[13]. Gonococci express 8–11 antigenically distinct proteins that
are encoded by separate opa genes [14,15]. Mature Opa proteins
are predicted to have four surface-exposed loops, namely, one
semi-variable (SV) loop, two hypervariable (HV1 and HV2)
loops, and one conserved (4L) loop [16]. Sequence differences in
the HV regions are responsible for the antigenic identity of each
Opa protein as well as slight differences in molecular weight.
Each opa gene undergoes phase variation via a frame shift
mechanism, and therefore, a single gonococcus can express no
Opa proteins, one Opa protein, or multiple Opa proteins
simultaneously [17,18].
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important during urogenital tract infections. The majority of
urethral isolates from naturally [19] and experimentally infected
men [20,21] expressed one or more Opa proteins, and in women,
mostly Opa-positive isolates were recovered from the cervix during
certain stages of the menstrual cycle [19]. Evidence for Opa
protein expression during infection is also supported by the
detection of Opa protein-specific antibodies in serum and genital
secretions from men and women with uncomplicated urogenital
tract infections, PID, or disseminated gonococcal infection
[22,23]. The presence of antibodies to multiple Opa proteins is
associated with a reduced risk of PID in commercial sex workers
[24], and therefore, Opa proteins may be protective vaccine
antigens.
While the HV loops are highly variable among Opa proteins,
the SV and 4L loops are relatively and highly conserved,
respectively and could be targeted in a vaccine. Immunization
with whole Opa proteins may prevent generation of high levels of
antibodies against the conserved loops due to the immunodomi-
nance of the HV loops [25]. Additionally, Opa-mediated
interactions with CEACAM1 on B and T lymphocytes during
immunization may decrease the effector functions of these
immune cells and thus prevent a robust vaccine-induced immune
response [26,27], although this hypothesis was not supported
experimentally [28]. To avoid these potential pitfalls and to test
whether the SV and 4L loops might carry broadly reactive,
protective epitopes, here we utilize peptide-based immunization
strategies to generate antibodies against the SV and 4L loops. Both
linear and cyclic peptides were used to generate antibodies based
on evidence that cyclic peptides induced bactericidal, conforma-
tion-dependant antibodies against meningococcal outer mem-
brane proteins [29]. Opa loop-specific antibodies were tested for
specificity, surface-binding, in vitro activity against N. gonorrhoeae
and the capacity to protect female mice from experimental genital
tract infection when delivered topically.
Results
Antibodies against the SV Loop and 4L Loop Are Broadly
Reactive
The 4L loop sequence of strain FA1090 is highly conserved with
only a single amino acid difference among the 8 Opa proteins
expressed by this strain. The SV loop is relatively well conserved
with the OpaA and OpaK proteins sharing the same SV loop
sequence and only 2–12 amino acid variations among the other 6
proteins (Figure 1). To test the hypothesis that antibodies against
the 4L and SV loops would be broadly reactive, we examined the
specificity of affinity-purified rabbit polyclonal antibodies against
linear peptides that correspond to the OpaA/K SV (AbSV linear)
and 4L (Ab4L linear) loop sequences by western blot. Ab4L linear
strongly recognized all of the Opa proteins of strain FA1090
except OpaE (Figure 2C) as reported previously [30]. AbSV linear
Figure 1. Conservation of SV and HV2 loop sequences. The predicted amino acid sequences of the SV and HV2 loops of the 8 Opa proteins of
strain FA1090 are shown. The sequences of the 36-mer cyclic peptides used to generate SV- and HV2BD-specific antisera are highlighted in grey. The
sequences of the linear peptides used to generate affinity-purified rabbit antibodies against the SV and HV2 loops are shown in light grey font.
doi:10.1371/journal.pone.0008108.g001
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and OpaI, which have an SV loop that is predicted to differ from
the OpaA/K SV sequence by 2 and 7 amino acids, respectively.
AbSV linear weakly recognized OpaD, which is predicted to differ
from the OpaA/K SV loop by 4 amino acids. When room
temperature-treated samples were analyzed, AbSV linear recognized
only OpaA, OpaK and OpaF. OpaD and OpaI proteins were not
recognized. AbSV linear did not recognize OpaB, which differs by 6
amino acids from the target peptide or OpaC or OpaE under
either condition, which differ from the OpaA/K SV sequence by
11–12 amino acids (Figures 2A and D).
We also immunized mice with cyclic peptides that correspond to
a longer surface-exposed region of the OpaA/K SV loop that does
not include any of the predicted transmembrane regions (Figure 1)
to increase the likelihood of generating conformation-dependent
antibodies [29]. The resultant antiserum, AbSV cyclic, was more
broadly reactive than AbSV linear and recognized all but 2 Opa
proteins of strain FA1090 when denatured samples were analyzed
(Figure 2B). AbSV cyclic recognized Opa proteins with up to 7
amino acid differences compared to the cyclic SV peptide, but not
OpaC or OpaE, which are the most divergent from OpaA/K in
the SV region (Figure 1). AbSV cyclic recognized OpaA, OpaK,
OpaD and OpaI proteins when RT-treated samples were used.
SV-Specific but Not 4L-Specific Antibodies Bind the
Bacterial Surface
The semi-quantitative surface-binding immunoblot (SBI) assay,
which utilizes whole gonococci, was used to compare the
concentration of antibodies needed for detectable binding to the
different Opa variants of strain FA1090. Affinity-purified rabbit
antibodies against linear HV2 loop peptides (AbHV2 linear) bound
homologous Opa variants in a dose-dependent manner (Figure 3A)
and not heterologous or Opa-negative variants. AbSV linear bound
only OpaA, OpaK and OpaF variants (Figure 3B), which is
consistent with western blot results against unheated lysates in
which native conformations are preserved. Approximately 10-fold
higher concentrations of AbSV linear were required to detect
binding to whole bacteria compared to AbHV2 linear (compare
Figures 3A and 3B). No specific binding was seen with Ab4L linear
at any concentration tested (Figure 3C).
The reactivity of the mouse antiserum against the cyclic SV
loop peptide in the SBI assay mirrored the broader reactivity
observed with this antiserum on western blots. AbSV cyclic bound
intact OpaA, OpaB, OpaD, OpaF, OpaK and OpaI variants
above background in the SBI assay at a dilution of 1:40, while
OpaC, OpaE, and Opa-negative variants were not recognized by
AbSV cyclic (Figure 3D). We also tested mouse antisera against a
cyclic peptide that corresponds to the HV2 loop of OpaB/D. As
predicted, AbHV2BD cyclic bound to OpaB variants better than
Opa-negative variants (Figure 3E). Consistent with the greater
surface exposure of the HV2 loop, a 5-fold higher dilution of
AbHV2BD cyclic produced a spot of similar intensity when tested
against OpaB variants as that of the AbSV cyclic antiserum
(compare Figures 3D and 3E).
IFA staining was performed as a second measure of surface-
binding. Consistent with the results obtained by SBI, AbSV linear
(2.2 mg/mL) bound OpaA variants as well as OpaK and OpaF-
expressing gonococci, but none of the other Opa variants.
AbSV cyclic bound the same set of Opa variants as recognized in
the SBI assay, but not OpaC or Opa-negative variants (Table 1).
As predicted from the SBI results, mouse antiserum against the
cyclic HV2BD peptide bound OpaB variants at a higher dilution
(1:100) than antiserum against the cyclic SV loop peptide (1:30).
Ab4L linear did not bind any Opa-positive gonococci at concentra-
tions of 1.2 mg/mL or 2.4 mg/mL (data not shown), a result that
confirms the negative SBI results with these antibodies (Table 1).
In summary, the IFA and SBI results were identical and
confirmed the predicted surface-exposure of the SV and HV2
loops. The need for increased concentration of SV loop-specific
Figure 2. Specificity of antibodies against the conserved Opa loops. Cell lysates of an Opa-negative variant and each of the 8 Opa–positive
variants of strain FA1090 were incubated at RT or 100uC prior to fractionation and incubated with (A and D)A b SV linear (1:75,000), (B and E)A b SV cyclic
(1:6,000), and (C)A b 4L linear (1:6,000). The broader reactivity of AbSV cyclic compared to AbSV linear is clearly shown whether native or denatured Opa
proteins are analyzed. Ab4L linear is even more broadly reactive in that it recognizes all denatured Opa proteins well except OpaE. None of the
antibodies recognize a protein in the Opa-negative lane (2). The location of a 25 kDa molecular weight marker is indicated, and the denatured Opa
proteins migrated at a slightly higher molecular weight than those incubated at RT, which is consistent with well characterized heat modifiable
nature of these proteins. The Ab4L linear immunoblot was kindly provided by Dr. Amy Simms.
doi:10.1371/journal.pone.0008108.g002
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accessible than the HV2 loop. We also conclude that the fourth
loop may not be accessible despite its predicted surface-exposure.
Alternatively, the linear 4L peptide may not induce antibodies that
recognize conformational epitopes present in the native protein.
Finally, we also demonstrated that the cyclic SV peptide induced
more broadly reactive antibodies compared to a linear peptide.
Bactericidal and Agglutination Activities
We next investigated whether cyclic or linear peptide-derived
antibodies against the SV or HV2-loops would be bactericidal.
Disappointingly, AbSV linear were not bactericidal against any of
the variants tested at concentrations ranging from 4.5–120 mg/mL
and the use of cyclic peptides to induce bactericidal antibodies
against the SV or HV2BD loops was also not successful when a
dilution as low as 1:9 was tested. Analysis of mouse antisera to
cyclic loop peptides showed IgG2a.IgG1.IgG2b.IgG3. In
contrast to mouse antisera against cyclic peptides, rabbit
antibodies against the linear HV2BD peptide, AbHV2BD linear, were
bactericidal against OpaB variants with a bactericidal50 concen-
tration of 40.4 mg/mL. Antibodies against the HV2 loop of Opa I,
AbHV2I linear, also demonstrated bactericidal activity against a
Figure 3. Detection of antibody surface-binding by the SBI assay. Opa-specific antibodies or antisera were serially diluted and incubated
with defined Opa variants spotted onto nitrocellulose filters and binding was detected as described in the Materials and Methods. Shown are the
normalized spot intensities plotted against the concentration of affinity-purified rabbit antibodies (AbHV2 linear,A b SV linear, and Ab4L linear) or dilution of
antisera (AbSV cyclic and AbHV2BD cyclic): (A)A b HV2 linear, (B)A b SV linear,( C)A b 4L linear (D)A b SV cyclic, (E)A b HV2BD cyclic. All results shown are representative
of at least two independent experiments. None of the antibodies bound Opa-negative gonococci. The results for AbHV2BD linear when tested against
Opa-negative variants are shown in panel A as an example.
doi:10.1371/journal.pone.0008108.g003
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mL. No other antibodies against HV2 linear peptides were
bactericidal against the corresponding homologous Opa variant.
Strain FA1090 is inherently resistant to the bactericidal activity
of NHS due to the binding of the complement regulatory protein
human C4b-binding protein (hC4BP) to its porin [31]. This
interaction is host-restricted [39]. Therefore, to better mimic
events that might occur when testing the activity of these
antibodies in the mouse infection model, we utilized strain
FA1090F62 por5–8, which produces a recombinant hybrid porin
that does not bind hC4BP and is thus serum sensitive. As observed
with wild type FA1090 bacteria, AbHV2BD linear but not the
AbHV2BD cyclic or AbSV cyclic mouse antisera was bactericidal
against OpaB variants of strain FA1090F62 por5–8 in the presence of
NHS. Control antibodies AbHV2A linear, which like AbHV2BD linear
are affinity-purified rabbit polyclonal antibodies, were not
bactericidal for OpaB variants of this serum sensitive strain
(Figure 4A). To further investigate this host restriction, we also
compared NHS with BBS as a nonhuman complement source.
For these experiments we utilized a constitutive OpaB-expressing
derivative of wild type strain FA1090 and a strain in which all the
opa genes have been inactivated. Consistent with the host
restriction for hC4BP, AbHV2BD linear exhibited 8-fold higher
activity against the OpaB-expressing strain when BBS was used
(bactericidal50 titers 1:36 (28 mg/mL) with NHS versus 1:288
(3.5 mg/mL) with BBS) (Figure 4B). AbHV2BD linear showed no
bactericidal activity against the Opa-deficient strain with either
complement source (data not shown).
The capacity to agglutinate bacteria may facilitate shedding of
bacteria in vaginal secretions and thus may be another important
effector function of antibodies. AbHV2BD cyclic agglutinated OpaB
variants at a titer of 1:200 with ,40 aggregates per 40X field
compared to only ,4 aggregates per field with the same dilution
of NMS. (Figure 4C). In contrast, AbHV2BD linear did not
agglutinate OpaB variants at dilutions as low as 1:2 (500 mg/
mL) (data not shown). AbSV cyclic agglutinated OpaA and OpaB
variants but not OpaK variants at a titer of 1:12.5 compared to
NMS (Figures 4C and D) although AbSV cyclic bound OpaK
variants. AbSV linear did not agglutinate any Opa variants tested
(data not shown).
HV2-Specific but Not SV-Specific Antibodies Reduce
Adherence to Cultured Cervical Cells
Antibody-mediated inhibition of Opa-mediated adherence and
invasion may also be protective. Most Opa proteins mediate
invasion of human cells via binding to human carcinoemybryonic
cellularadhesionmolecules(CEACAMs) [13].To testwhetherOpa
loop-specific antibodies can block gonococcal interactions with
human CEACAM-expressing endocervical cells, ME180 cells were
inoculated with the constitutive OpaB-expressing strain following
incubation with AbHV2BD linear,A b HV2BD cyclic,o rA b SV cyclic.
Treatment with AbHV2BD cyclic (Figure 5) but not AbSV cyclic
(data not shown) resulted in a dose-dependent decrease in the
number of cell-associated bacteria as compared to NMS. In
contrast there was no decrease in the number of cell-associated
bacteria when bacteria were treated with 0.25 mg/mL or 2.5 mg/
mL of AbHV2BD linear versus AbHV2C linear, which does not bind
OpaB variants (data not shown). We conclude AbHV2BD cyclic, but
not AbHV2BD linear block OpaB-mediated interactions with human
endocervical cells.
Figure 4. Bactericidal and agglutination activities. The bactericidal activity of SV and HV2 loop-specific antibodies was measured against (A)
OpaB variants of the serum sensitive strain FA1090F62por 5–8 in the presence of 1% NHS and (B) the constitutively OpaB-expressing strain of FA1090
(SR) incubated with AbHV2BD linear in the presence of NHS or BBS. Results are expressed as the percent of bacteria recovered compared to wells with
no antibody present. Only AbHV2BD linear was bactericidal against the OpaB-expressing serum sensitive strain. The use of a non-human complement
source (BBS) resulted in ,8-fold greater bactericidal activity for AbHV2BD linear against serum resistant (wild type) OpaB-expressing variants.
AbHV2BD linear was not bactericidal when HI-NHS and HI-BBS were used (data not shown). Agglutination activity was measured as the average number
of bacterial aggregates following incubation of (C) OpaB variants with increasing dilutions of AbHVBD cyclic,A b SV cyclic, or NMS and (D) OpaA or OpaK
variants with AbSV cyclic or NMS. Antibodies raised to the cyclic SV peptides showed agglutinating activity except when tested against OpaK variants.
doi:10.1371/journal.pone.0008108.g004
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The CEACAM residues that are important for Opa-mediated
adherence are not conserved in the murine CEACAM1 [30,40],
and consistent with this host restriction, we have not observed
Opa-mediated adherence to two different murine epithelial cell
lines (J. G. Cole et al, manuscript submitted). However, female
mice can be experimentally infected with N. gonorrhoeae despite the
absence of human CEACAMs [30,32], and Opa-specific antibod-
ies could prevent or reduce colonization of mice through
bactericidal activity, opsonophagocytic uptake, or agglutination
with subsequent shedding. Additionally, because selection for Opa
expression occurs during experimental infection of BALB/c mice
for reasons that are not known [30], Opa-specific antibodies may
block other Opa-mediated functions [38]. We therefore tested the
capacity of Opa loop-specific antibodies to reduce gonococcal
colonization of BALB/c mice when administered vaginally as
done in protection studies for other sexually transmitted pathogens
[37,41–43].
First, to determine how long antibodies remain in the vagina
after topical administration, groups of mice were inoculated
vaginally with 20 ml of PBS containing 10 mgo fA b HV2 linear, and
the amount of rabbit IgG in vaginal washes was measured over
time. A 50% decrease in the amount of rabbit IgG recovered was
observed between 2 and 15 min post-inoculation. Antibody levels
were maintained for at least another 45 min, after which a gradual
decline was observed over the next 4 hours. Low levels of antibody
were detected in all but one mouse at 9, 12, and 24 hrs post-
inoculation (Figure 6). No rabbit IgG was detected in vaginal
washes from untreated control mice and there was no correlation
between persistence of antibody and the stage of estrous at the
time of inoculation. Based on these data we concluded that
antibody must function within the first 24 hrs to be effective, and
thus chose to analyze colonization loads only at early time points
(days 1, 2, and 3 post-inoculation). We also chose a challenge dose
of 10
3 CFU for subsequent protection experiments based on pilot
experiments that showed this dose resulted in colonization by
strain FA1090 for at least three days in 85% percent of mice.
We first tested AbSV linear to address our main objective of
developing broadly-reactive protective antibodies against N.
gonorrhoeae. Mice were inoculated with 10
3 OpaA variants that were
preincubated with AbSV linear,A b HV2A linear,o rA b HV2BD linear.
OpaA variants were used since AbSV linear bound OpaA variants
(Figure 3B and Table 1). There was no significant difference
in the number of gonococci recovered on days 1 and 2 post-
inoculation when results from the AbSV linear and AbHV2A linear
groups were compared to the AbHV2BD linear control group
(Figure 7A). We also tested AbSV cyclic, which may recognize
conformational epitopes among Opa proteins compared to
AbSV linear.A b SV cyclic bound OpaB variants well in the SBI and
IFA assay, and we therefore assessed the capacity of AbSV cyclic and
AbHV2BD cyclic to passively protect mice from OpaB variants.
Incubation of OpaB variants with AbHV2BD cyclic or AbSV cyclic did
not result in a significant difference in colonization load (Figure 7B)
or percent of test mice colonized on day 3 compared to the NMS
control group (data not shown). In summary, despite binding to the
bacterial surface, antibodies against the SV loop do not reduce N.
gonorrhoeae colonization, even when a cyclic peptide is used to better
mimic the loop conformation.
None of the HV2-specific antibodies that we tested as potential
positive controls in studies with SV loop-specific antibodies
showed protection. Results from initial pilot studies suggested
Figure 5. Antibody-mediated inhibition of gonococcal associ-
ation with tissue culture cells. Pre-incubation with AbHV2BD cyclic but
not AbSV cyclic decreased the total number of ME180 cell-associated
OpaB-expressing gonococci when an antiserum dilution of 1:30 was
used. Shown is the average percent of cell-associated bacteria that were
preincubated with AbHV2BD cyclic (test) or NMS (control) based on
combined data from three independent assays. A two-tailed, unpaired
Student’s t-test was used to assess statistical differences between test
and control wells.
doi:10.1371/journal.pone.0008108.g005
Figure 6. Duration of topically applied antibodies in the
vagina. A fifty percent reduction in the concentration of topically
applied rabbit antibodies was detected in vaginal washes collected 1 hr
post-inoculation compared to a 2 min time point. Antibody levels
decreased further over time. The limit of detection was 7.8 ng/ml. (A)
Concentration of rabbit IgG (mg/ml) in mouse vaginal washes was
determined in duplicate by capture ELISA. (B) The percent of antibody
remaining relative to the average 2 minute value is shown for each time
point. Results are combined from two experiments and each animal
was used for a single time point (n=2–3 mice per time point).
doi:10.1371/journal.pone.0008108.g006
Opa-Specific Antibody Function
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3 CFU of OpaB variants incubated
with 5 mgA b HV2BD linear would be protective in passive protection
studies. Unlike AbHV2BD cyclic,A b HV2BD linear were bactericidal,
and therefore, we performed a larger scale experiment to test the
capacity of AbHV2BD linear to protect mice challenged with OpaB
variants. Significantly fewer bacteria were recovered from mice in
the AbHV2BD linear test group compared to mice for which
AbHV2A linear was used as a negative control (p#0.03) on days 1
and 2 post-inoculation. However, this difference was not observed
in two subsequent experiments and statistical analysis of combined
data from all three experiments showed no significant decrease in
recovery of gonococci from mice inoculated with AbHV2BD linear-
treated OpaB variants on days 1 and 2 post-inoculation compared
to AbHV2A linear-treated bacteria (p=0.07 and p=0.08, respec-
tively) (Figure 7C). There was also no difference in the number of
mice colonized in each group with 60% of the AbHV2BD linear and
71% of the AbHV2A linear-treated mice infected on day 1 (p=0.45).
We considered the possibility that subpopulations of gonococci
that express a different Opa protein than that of target variant
were responsible for the colonization of test groups. However, the
distribution of Opa phenotypes of vaginal isolates on day 1 did not
differ significantly from that of the inoculum in any experiment.
We conclude that none of the HV2-specific antibodies tested are
protective against N. gonorrhoeae colonization, including antibodies
with bactericidal activity, and the lack of effectiveness of these
antibodies in vivo is not due to escape variants establishing
infection.
Discussion
N. gonorrhoeae is a highly successful Gram-negative bacterium
that is noted for the antigenic variability of its surface and the
frequency by which it causes repeat infections. Opa proteins are
expressed during infection and have two conserved loops, the SV
and 4L loops, which could be targeted in a vaccine. Here we
analyzed antibodies against peptides that correspond to the SV
and 4L loops for the capacity to bind to gonococci that express
different Opa proteins and for correlates of antibody-mediated
protection. Antibodies against linear or cyclic peptides that
correspond to the SV loop recognized intact gonococci as assessed
Figure 7. Passive protection experiments. Mice were inoculated with OpaA or OpaB variants that were preincubated with antibodies against
linear or cyclic Opa SV or HV2-loop sequences. (A) OpaA variants with AbSV linear,A b HV2A linear,o rA b HV2BD linear. There was no difference in the number
of gonococci recovered from mice in the AbSV linear and AbHV2A linear test groups compared to the AbHV2B linear control group on days 1 or 2 post-
inoculation (p#0.14). (B) OpaB variants with AbHV2BD cyclic,A b SV cyclic or NMS. There was no difference in the number of gonococci recovered from
mice treated with AbSV cyclic compared to the control (NMS) group (p#0.20) on days 1 or 2 post-inoculation. (C) OpaB variants with AbHV2BD linear and
AbHV2A linear. Shown are combined data from three independent experiments that showed no difference in the number of bacteria recovered from
each group on days 1 and 2 post-inoculation at the level of p=0.07 and p=0.08, respectively (n=7–15 mice/group in each experiment; total
number=35 mice/group). Symbols indicate a single animal and horizontal bars indicate the group mean with the SEM shown. Statistical differences
were analyzed by a two-tailed Student’s t test.
doi:10.1371/journal.pone.0008108.g007
Opa-Specific Antibody Function
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against cyclic SV peptides bound the surface of 6 of the 8 Opa
variants of strain FA1090, including Opa variants with 7 amino
acid differences from the target peptide. In contrast, 4L-specific
antibodies did not bind the bacterial surface. The cyclic SV loop
peptide also induced antibodies with agglutination ability, while
the SV linear peptide did not. The broader reactivity and
agglutinating ability of AbSV cyclic may be explained by the fact
that the cyclic SV peptide was longer (36 amino acids) than the
linear peptides (20 amino acids) and included more conserved
regions of the loop. Cyclic peptides may therefore carry more
conserved epitopes, T-cell epitopes, and possibly conformational
epitopes that are shared by Opa proteins with a less related
primary sequence. Interestingly, bactericidal activity was only
exhibited by antibodies against linear peptides. This result was in
contrast to the demonstration that cyclic peptides were more
successful for inducing bactericidal antibodies against the class 1
protein of N. meningitidis [29].
With regard to the difference in bactericidal activity between
AbHV2BD linear and AbHV2BD cyclic, one should consider the fact
that the antibodies were produced in different animal species and
that AbHV2BD linear were high titer affinity-purified antibodies.
Antibodies generated by the linear or cyclic SV loop peptides were
not bactericidal, however, even when rabbit serum was used as a
complement source to by-pass the host-restricted serum resistance
of this strain. It is possible that a different adjuvant might improve
the potential of the SV loop as a vaccine target by promoting the
induction of bactericidal antibodies.
We also showed that the species used as the complement source
in bactericidal assays is important when examining the bactericidal
activity of vaccine-induced antibodies against SR strains of N.
gonorrhoeae. Some P1B strains, like strain FA1090 are resistant to
NHS due to the binding of human C4BP to the P1B molecule
[31], which reduces activation of the classical pathway and
subsequent bacteriolysis [44]. Here we demonstrated that
AbHV2BD linear killed OpaB variants of a SS derivative of strain
FA1090 better than SR wild type OpaB variants when NHS was
used as the complement source. AbHV2BD linear was also more
bactericidal against OpaB variants of strain FA1090 when rabbit
serum was used. These results illustrate the importance of
considering the complement source in bactericidal assays designed
to predict vaccine efficacy in humans versus laboratory animals.
Ideally, antibodies that are strongly bactericidal against SR strains
in the presence of NHS are desired.
A vaccine-induced immune response against Opa proteins
could also block Opa-mediated adherence and invasion, which has
been the focus of vaccine studies on meningococcal Opa proteins.
de Jonge et al. [25,28] reported that antibodies raised against
purified recombinant Opa proteins, outer membrane protein
vesicles containing Opa proteins, or liposomes containing
recombinant Opa proteins from N. meningitidis elicited an antibody
response, which while not always bactericidal, blocked Opa-
CEACAM interactions on tissue culture cells [25]. Here we
showed AbHV2BD cyclic but not SV-specific antibodies decreased
the total number of bacteria associated with CEACAM-expressing
endocervical cells. The inability to block adherence with SV-
specific antibodies is in accordance with studies on N. meningitidis
Opa proteins that show the SV loop is not involved in CEACAM-
binding [46]. Other Opa protein functions are likely to exist,
however, that could perhaps be blocked by an SV loop-specific
immune response. For example, Opa-expressing gonococci are
preferentially recovered from experimentally infected male
volunteers [20,21] and during lower genital tract infection of
female mice [30]. The basis for this selection is not known, and the
inability to detect CEACAMs on primary male urethral cells [47]
and the dissimilarities between human and murine CEACAM1
[40,48] suggest Opa proteins may play other important roles
during infection [49].
Finally, SV loop-specific and selected HV2 loop-specific
antibodies showed no protection in mice when mixed with the
homologous variant prior to vaginal inoculation. We conclude the
SV or HV2 Opa protein loops may not be effective targets for
antibody-mediated protection. It is possible, however, that
technical limitations may have prevented us from detecting a
protective effect. The concentration of antibodies may not have
been high enough and similar to that reported by Sherwood et al.
[50], antibodies were gradually lost within 24 hrs post-inoculation.
Clearance via opsonophagocytosis might not occur during this
time frame since phagocytes are not detected in infected murine
tissue until 2 to 5 days post-inoculation [38]. Systemic delivery of
antibodies to the vagina has been successful for others. For
example, monoclonal IgA against Chlamydia trachomatis was
detected in mouse vaginal secretions for up to 48 hrs when
delivered intraperitoneally [37], and Parr et al. [41] reported
intraperitoneal administration of IgG resulted in the detection of
specific IgG 48 hours later in vaginal secretions at levels equal to
3% of that found in the vaginal secretions of immunized mice. We
have detected rabbit IgG in vaginal washes for as long as 60 hrs
after intraperitoneal or intravenous injection of high titer rabbit
polyclonal antiserum against whole gonococci (B.T. Mocca and
A.E. Jerse, unpublished data). However, we did not detect
gonococcal-specific antibodies in vaginal washes following intra-
venous injection of the affinity-purified HV2-specific rabbit
antibodies used in this study, and we therefore chose to deliver
the antibodies topically.
In summary, we have demonstrated that broadly-reactive
antibodies can be generated against a relatively conserved Opa
protein loop that bind to the bacterial surface and have
agglutination ability. These antibodies could potentially recognize
many Opa variants produced by different gonococcal strains and
therefore, the use of different adjuvants or other strategies to
induce high titered SV loop-specific antibodies with bactericidal
activity that can be delivered systemically is warranted. The in
vitro and in vivo experiments described here should be useful in
the development of other vaccine antigens against gonorrhea.
Materials and Methods
Strains and Culture Conditions
Neisseria gonorrhoeae strain FA1090 [porB1b, streptomycin resis-
tant, serum resistant (SR)] was originally isolated from a female
patient with disseminated gonococcal infection. Strain FA1090
expresses 8 antigenically distinct Opa proteins: OpaA, OpaB,
OpaC, OpaD, OpaE, OpaF, OpaI and OpaK. Frozen stocks of
each Opa variant were prepared as described [30]. Stock Opa
variants expressed LOS species with the same banding pattern on
silver stained tricine gels (data not shown) and stocks composed of
either mostly piliated or nonpiliated variants were maintained.
Strain FA1090F62por5–8 is a serum sensitive (SS) derivative of strain
FA1090 in which porin loops 5–8 were replaced with loops 5–8 of
the SS strain F62 as described by Ram et al. (kindly provided
by Sanjay Ram, University of Massachusetts) [31]. Strain
FA1090F62 por5–8 is sensitive to NHS, and does not bind human
C4b-binding protein (hC4BP). OpaA, OpaF, and Opa-negative
variants were isolated from OpaB-expressing FA1090F62por5–8
bacteria after 2–3 serial passages of individual colonies that were
screened by colony suspension immunoblots with HV2-specific
antibodies as described [30,32]. Where indicated, recombinant
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constitutively express only OpaB were used (kindly provided by
Janne Cannon, University of North Carolina). N. gonorrhoeae was
cultured on GC agar (Difco) with Kellogg’s supplement [33] and
0.2 mM Fe(NO3)3 at 37uC under 7% CO2. GC-VCNTS agar (GC
agar with vancomycin, colistin, nystatin, trimethoprim, and
streptomycin sulfate) was as described [32].
Generation of Antibodies
Two general types of antibodies were evaluated in this study,
specifically affinity-purified rabbit polyclonal antibodies against
linear peptides (Ablinear) and mouse antisera raised against cyclic
peptides (Abcyclic). Ab4L linear,A b HV2A linear,A b HV2BD linear,
AbHV2C linear,A b HV2F linear,A b HV2I linear, and AbHV2K linear
antibodies were previously described [30]; here we obtained SV-
loop specific rabbit antibodies (AbSV linear), which were generated
against a linear 20 amino acid peptide (DYPEPTGAKKGKIST-
VSDYF) that corresponds to the SV loop of OpaA and OpaK
(OpaA/K) of strain FA1090 (Figure 1). Peptide synthesis, rabbit
immunizations, and affinity purification were performed by Bethyl
Laboratories (Montgomery, Texas). Rabbit antibodies were
dialyzed (50 kDa exclusions pore size) (Spectrum Laboratories
Inc, Racho Dominguez, CA) to remove the 0.1% sodium azide
that was added during preparation. We also generated mouse
antisera (AbSV cyclic and AbBD cyclic) to two cyclic peptides that cor-
respond to the SV loop sequence of OpaA/K (AAERITHDY-
PEPTGAKKGKISTVSDYFRNIRTHSIH; 36-mer) or the HV2
loop sequence that is common to OpaB and OpaD (OpaB/D)
(IDSTKKITGTLTAYPSDADAAVTVYPDGHPQKNTYQ; 36-
mer). Cyclic peptides were synthesized by Celtek Peptides
(Nashville, TN) through the addition of a disulfide bond between
added terminal cysteine residues, and six week-old female BALB/c
mice were immunized subcutaneously three times at three week
intervals with 50 mg of peptide suspended in TiterMax Gold
(Sigma Chemical Co, St. Louis, MO). Blood was collected two
weeks after the final boost, and individual samples were analyzed
by enzyme linked immunosorbent assay (ELISA) for peptide-
specific antibody titers essentially as described [34]. Briefly, 96-well
plates were coated with 5 mg of the cyclic peptide in 50 mM
NaHCO3 (pH 9.6), and incubated with three-fold dilutions of
mouse sera followed by goat anti-mouse IgG (c chain-specific)
conjugated to horseradish peroxidase (HRP) and HRP substrate
(Sigma). Absorbance was read at 405 nm on an EL800 Universal
Microplate Reader (Bio-Tek Instruments, Winooski, VT) and
analyzed with KC Junior software (Bio-Tek Instruments).
Background was set at 3 standard deviations above the average
A405 readings of 3 wells to which no primary antibody was added.
Sera with titers .1:7,290 were pooled and frozen at 220uC. The
relative levels of IgG isotypes within Opa loop-specific mouse
antisera were measured with a mouse antibody isotyping kit (Bio-
Rad Laboratories, Hercules, CA) as per the manufacturer’s
instructions.
Immunoblots
For western blots, bacteria were suspended in lithium acetate
buffer and incubated in Laemmli buffer (Sigma) containing
sodium dodecyl sulfate (SDS) and b-mercaptoethanol for 10 min
at 100uC to denature the samples or at room temperature (RT) to
preserved native conformations. Samples were fractionated on
11.5% SDS polyacrylamide gels and transfered to polyvinylidene
fluoride (PVDF) membranes. After blocking in 0.5% Tween 20,
membranes were incubated with AbSV linear (1:75,000), Ab4L linear
(1:6,000), or AbSV cyclic (1:6,000), followed by goat anti-rabbit IgG
HRP (1:50,000) (Bethyl Laboratories) or anti-mouse IgG HRP
(1:50,000) (Sigma). Primary and secondary antibodies were diluted
in block, and blots were washed three times in PBS with 0.05%
Tween 20 after each incubation. Detection was with ECL
detection reagent (Amersham Biosciences) as per the manufactur-
er’s instructions. Attempts to utilize an ELISA with whole bacteria
as the antigen to measure surface-binding were not successful due
to the bacteria not adhering well enough to the wells. Therefore, a
semi-quantative surface-binding immunoblot (SBI) similar to that
described by Afonina et al. [35] was used to measure the binding
of antibodies to intact gonococci. Bacteria of the Opa phenotype
to be tested were suspended in PBS to an A600 of 0.20 and diluted
1:20 in PBS. One hundred microliters (,5610
5 CFU) of the final
suspensions were applied to a nitrocellulose membrane via a 96-
well vacuum manifold apparatus (Schleicher & Schuell, Keene,
NH). The membrane was dried at RT, incubated for 30 min at
37uC, and then blocked for 1 hr in PBS with 3% BSA (Sigma).
The filter was returned to the manifold and individual wells were
incubated for 1 hr with 100 mL of two-fold serial dilutions of
affinity-purified rabbit antibodies (AbSV linear,A b 4L,A b HV2 linear;
range 8.2–720 ng) or mouse antisera (Absv cyclic,A b HV2BD cyclic;
range 1:20–1:320). Positive control wells were incubated with
serial dilutions of rabbit polyclonal antiserum against heat-killed
FA1090 bacteria (1:4,000–1:64,000) or the porin-specific mono-
clonal antibody B2E8 (1:250–1:4,000) (A.E. Jerse and Mary
Petzke, unpublished data). All antibodies were diluted in PBS with
3% BSA, and secondary detection, washes, and exposure of the
membranes to substrate were as for western blots. Spot intensities
were quantified by densitometry (Image J Version 1.37v) and the
mean intensity of three wells incubated without primary antibody
was subtracted from that of wells with Opa-specific antibodies (test
wells) or anti-whole bacteria or B2E8 antibodies (control wells).
The spot intensities of the control wells were plotted against the
antibody concentration (Ablinear, rabbit) or antiserum dilution
(Abcyclic, mouse), and values that fell within the linear regions of
the curves were used to normalize for slight differences in the
number of bacteria in each spot. Normalized data were obtained
by dividing the mean intensity of the test wells by that of the
appropriate control well (mouse or rabbit antibody).
Indirect Fluorescent Antibody (IFA) Staining
Single colonies of FA1090 Opa variants were suspended in
water, applied to IFA slides (Electron Microscopy Sciences,
Hatfield, PA), and fixed in 100% methanol at 220uC after drying
at RT. Slides were blocked for 1 hr in PBS with 0.1%
immunoglobulin-free BSA (Sigma) (blocking buffer). Slides were
incubated with primary antibodies for 1 hr at the following final
concentrations or dilutions, which were determined empirically:
AbHV2 linear (0.87–1.2 mg/mL), AbSV linear (2.2 mg/mL), Ab4L linear
(2.4 mg/ml), and AbHV2 cyclic (1:100) and AbSV cyclic (1:30).
Secondary antibodies were goat anti-rabbit or goat anti-mouse
IgG conjugated to AlexaFluor 488 (Invitrogen, Carlsbad, CA)
(1:500) and incubations were for 30 min. All antibodies were
diluted in blocking buffer and wells were washed five times with
PBS after each incubation. Antibodies specific for the HV2 loop of
each Opa variant were used as positive controls (0.87–1.2 mg/mL)
in all IFA assays; polyclonal rabbit antisera against heat-killed
FA1090 (1:1,000) was used as a positive control for Opa-negative
variants; negative controls were antibodies against heterologous
HV2 loops and wells that were not incubated with primary
antibodies. Slides were examined with an Olympus BX60 system
microscope with a BX-FLA reflected light fluorescence attachment
and Olympus U-M41001 filter. All images were obtained with a
SPOT charge-coupled-device digital camera (Diagnostic Instru-
ments Inc., Sterling Heights, MI).
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Bactericidal assays against wild type FA1090 Opa variants
were performed in microtiter plates using 10% normal human
serum (NHS) (Quidel Corporation, San Diego, CA) or 1% baby
bunny serum (BBS) (AbD Serotec, Raleigh, NC) as the
complement source. For assays that used strain FA1090F62por5–8,
1% NHS was used. These serum concentrations are .2-fold
lower than that concentration that showed no killing of the target
strains in the absence of added antibody as determined by Garvin
et al [36]. For testing Opa loop-specific antibodies, Ablinear or
Abcyclic were serially diluted in minimal essential medium (MEM)
(final volume 150 ml), and 50 mlo fd i l u t e dN H So rB B Sw e r e
added to each well to achieve the final serum concentrations
stated above based on a final 250 ml volume. Bacteria to be tested
were harvested from solid GC agar after 20–22 hrs growth,
suspended in MEM, and 50 ml containing 1.5–2.5610
3 CFU
were added to each well. Plates were incubated at 37uCi n7 %
CO2 for 1 hr, after which 50 ml of GCB were added and mixed.
Two 50 ml aliquots were cultured on GC agar and the average
number of CFU recovered was determined. The bactericidal50
titer was that concentration of antibody that resulted in a 50%
reduction in the number of CFU recovered from wells that
contained serum but no added test antibodies. Polyclonal rabbit
antiserum against whole gonococci, which showed high level
bactericidal activity against all Opa variants tested, was used as a
positive control and antibodies that do not bind the target strain
were used as negative controls. Heat-inactivated (HI) NHS and
BBS were prepared by incubation at 56uC for 30 min, and were
tested in parallel for each assay; none of the test or control
antibodies had activity when HI serum was used. At least two
independent experiments were performed for each test antibody,
and the results were similar.
Agglutination Assay
Agglutination titers were determined by the method of Pal et al
[37]. Bacteria from primary subcultures of frozen stocks of Opa
variants were suspended in PBS and passed through a 1.2 mm
pore to remove aggregates. Filter suspensions were adjusted to an
A600 of 0.4. Test antibodies or antisera were serially diluted 2-fold
and 10 mL of each dilution were incubated with 10 mL of bacteria
(,5610
6 CFU) at 37uC in a microtiter plate for 45 min. Bacteria
were incubated with the same dilutions of normal mouse sera
(NMS) or affinity-purified polyclonal rabbit antibodies against
heterologous HV2 loops in parallel. After incubation, 5 mL were
spotted on a glass slide and stained with HEMA3 (Exaxol Corp).
The average number of aggregates per at least three 40X fields
was determined under light microscopy. Agglutination titers were
defined as the highest dilution of test antibodies that caused
greater than three times the number of aggregates seen in the
same dilution of NMS or control antibodies. Comparisons
between piliated and non-piliated variants of the same Opa type
were also performed and identical results were obtained (data not
shown).
Passive Protection Experiments
Female BALB/c mice 6–8 weeks of age (National Cancer
Institute, Frederick, MD) were treated with 1.5 mg water-soluble
17b-estradiol (Sigma) and antibiotics to promote susceptibility to
N. gonorrhoeae as described [38]. In pilot experiments, 5–8 mice per




predominantly OpaB-variants that were pre-incubated in PBS
with 250 or 500 mg/ml of AbHV2BD linear or in PBS alone for
20 min at 37uC. In subsequent experiments with loop-specific
affinity purified rabbit antibodies, bacteria (,5610
4 CFU/ml)
were preincubated in PBS with 250 mg/ml of AbHV2A linear,
AbHV2BD linear, or AbSV linear and 20 ml of the suspension
(,10
3 CFU and 5 mg of antibodies) were inoculated vaginally
into mice (n=7–15 mice per group). In studies with mouse
antisera against cyclic peptides, mice were inoculated with a 20 ml
suspension containing 6610
3 CFU that were preincubated with
AbHV2BD cyclic,A b SV cyclic, or NMS (final dilution of antiserum or
NMS, 1:30) (n=10–11 mice per group). For all experiments,
vaginal mucus was quantitatively cultured for N. gonorrhoeae daily
for 3 days as described [32].
Measurement of Antibody Duration
In separate experiments, the amount of topically applied
antibody recovered from the vagina was measured over time by
inoculating 23 untreated, 6 week-old female BALB/c mice
vaginally with 20 mL of PBS containing 10 mg of affinity-
purified rabbit polyclonal Opa-specific antibodies. The vaginas
of 2–3 mice per time point were washed 3 times with 40 mLP B S
and the three samples from each mouse were pooled (,120 mL)
and centrifuged at 13,000 rpm for 3 min. Supernatants were
frozen at 220uC. Control samples were collected from 3
untreated mice. The concentration of rabbit IgG in murine
vaginal washes was measured with the Rabbit IgG Quantitative
Kit ELISA (Bethyl Laboratories). Animal experiments were
conducted in the laboratory animal facility at USUHS, which is
fully accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care, under a protocol
approved by the USUHS Institutional Animal Care and Use
Committee.
Adherence Assay
ME180 cervical epithelial cells (ATCC, Manassas, VA) were
grown to near confluency in 24-well tissue culture plates in
McCoy’s 5A medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Quality Biological Inc., Gaithersburg,
MD) and 2.2 g/L sodium bicarbonate. Non-piliated OpaB-
expressing bacteria were subcultured from the freezer and passed
once to GC agar before being suspended in McCoy’s 5A medium
supplemented with 2.2 g/L sodium bicarbonate and 5 mg/L
Fe(NO3)3 to an A600 of 0.07. Bacterial suspensions were diluted
1:10 and pre-incubated for 5 min with mouse antisera against
HV2 or SV cyclic peptides (test) or NMS (negative control) (final
dilutions 1:30 and 1:100), or with 0.25 mg/mL or 2.5 mg/mL of
AbHV2BD linear (test) or AbHV2C linear (negative control). Bacterial
suspensions (500 ml) were applied to cells (multiplicity of infection,
10:1) in triplicate wells. After 2 hrs at 37uCi n7 %C O 2,
monolayers were washed four times with PBS to remove
nonadherent bacteria. Cells were lysed with 0.5% saponin (Sigma)
and the number of cell-associated bacteria was determined by
serial dilution and culture of the saponin-treated supsensions.
Results are expressed as the number of cell-associated bacteria
divided by the number of bacteria in the inoculum (% cell-
associated). The average percent of cell-associated bacteria
recovered from in test and control wells was calculated from
three independent experiments that were each performed in
triplicate. Standard error bars are shown.
Statistical Analysis
A Fishers Exact test was used to compare the number of mice
colonized in each experimental group in passive protection
experiments. Differences in the number of gonococci recovered
from mice and the recovery of cell-associated gonococci in tissue
culture experiments were analyzed by the Student’s t-test.
Opa-Specific Antibody Function
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8108Acknowledgments
We thank Afrin Begum and Jana Jones for expert technical assistance with
bactericidal assays and the SBI assay, respectively, and Dr. Cara Olsen for
help with statistical analysis.
Author Contributions
Conceived and designed the experiments: JGC AEJ. Performed the
experiments: JGC. Analyzed the data: JGC AEJ. Wrote the paper: JGC
AEJ.
References
1. McNabb SJ, Jajosky RA, Hall-Baker PA, Adams DA, Sharp P, et al. (2008)
Summary of notifiable diseases–United States, 2006. MMWR Morb Mortal
Wkly Rep 55: 1–92.
2. Gerbase AC, Rowley JT, Heymann DH, Berkley SF, Piot P (1998) Global
prevalence and incidence estimates of selected curable STDs. Sex Transm Infect
74 Suppl 1: S12–16.
3. Hook EW, Handsfield HH (1999) Gonococcal Infections in the adult. In:
Holmes KK, Mardh P-A, Sparling PF, Lemon SM, Stamm WE, et al. Sexually
Transmitted Diseases. 3rd ed. New York: McGraw-Hill. pp 451–466.
4. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, et al. (1997)
Reduction of concentration of HIV-1 in semen after treatment of urethritis:
implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi
Research Group. Lancet 349: 1868–1873.
5. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL (2004) The estimated
direct medical cost of sexually transmitted diseases among American youth,
2000. Perspect Sex Reprod Health 36: 11–19.
6. Tapsall JW (2005) Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 41
Suppl 4: S263–268.
7. CDC (2007) Update to CDC’s sexually transmitted diseases treatment
guidelines, 2006: fluoroquinolones no longer recommended for treatment of
gonococcal infections. MMWR Morb Mortal Wkly Rep 56: 332–336.
8. Faruki H, Kohmescher RN, McKinney WP, Sparling PF (1985) A community-
based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not
producing penicillinase (chromosomally mediated resistance). N Engl J Med 313:
607–611.
9. Fox KK, Thomas JC, Weiner DH, Davis RH, Sparling PF, et al. (1999)
Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae.
Am J Epidemiol 149: 353–358.
10. Hobbs MM, Alcorn TM, Davis RH, Fischer W, Thomas JC, et al. (1999)
Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of
porin during passage within a community. J Infect Dis 179: 371–381.
11. Plummer FA, Simonsen JN, Chubb H, Slaney L, Kimata J, et al. (1989)
Epidemiologic evidence for the development of serovar-specific immunity after
gonococcal infection. J Clin Invest 83: 1472–1476.
12. Buchanan TM, Eschenbach DA, Knapp JS, Holmes KK (1980) Gonococcal
salpingitis is less likely to recur with Neisseria gonorrhoeae of the same principal
outer membrane protein antigenic type. Am J Obstet Gynecol 138: 978–980.
13. Dehio C, Gray-Owen SD, Meyer TF (1998) The role of neisserial Opa proteins
in interactions with host cells. Trends Microbiol 6: 489–495.
14. Dempsey JA, Litaker W, Madhure A, Snodgrass TL, Cannon JG (1991) Physical
map of the chromosome of Neisseria gonorrhoeae FA1090 with locations of genetic
markers, including opa and pil genes. J Bacteriol 173: 5476–5486.
15. Bhat KS, Gibbs CP, Barrera O, Morrison SG, Jahnig F, et al. (1991) The
opacity proteins of Neisseria gonorrhoeae strain MS11 are encoded by a family of 11
complete genes. Mol Microbiol 5: 1889–1901.
16. Malorny B, Morelli G, Kusecek B, Kolberg J, Achtman M (1998) Sequence
diversity, predicted two-dimensional protein structure, and epitope mapping of
neisserial Opa proteins. J Bacteriol 180: 1323–1330.
17. Murphy GL, Connell TD, Barritt DS, Koomey M, Cannon JG (1989) Phase
variation of gonococcal protein II: regulation of gene expression by slipped-
strand mispairing of a repetitive DNA sequence. Cell 56: 539–547.
18. Stern A, Brown M, Nickel P, Meyer TF (1986) Opacity genes in Neisseria
gonorrhoeae: control of phase and antigenic variation. Cell 47: 61–71.
19. James JF, Swanson J (1978) Studies on gonococcus infection. XIII. Occurrence
of color/opacity colonial variants in clinical cultures. Infect Immun 19: 332–340.
20. Swanson J, Barrera O, Sola J, Boslego J (1988) Expression of outer membrane
protein II by gonococci in experimental gonorrhea. J Exp Med 168: 2121–2129.
21. Jerse AE, Cohen MS, Drown PM, Whicker LG, Isbey SF, et al. (1994) Multiple
gonococcal opacity proteins are expressed during experimental urethral infection
in the male. J Exp Med 179: 911–920.
22. Lammel CJ, Sweet RL, Rice PA, Knapp JS, Schoolnik GK, et al. (1985)
Antibody-antigen specificity in the immune response to infection with Neisseria
gonorrhoeae. J Infect Dis 152: 990–1001.
23. Zak K, Diaz JL, Jackson D, Heckels JE (1984) Antigenic variation during
infection with Neisseria gonorrhoeae: detection of antibodies to surface proteins in
sera of patients with gonorrhea. J Infect Dis 149: 166–174.
24. Plummer FA, Chubb H, Simonsen JN, Bosire M, Slaney L, et al. (1994)
Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal
salpingitis. J Clin Invest 93: 1748–1755.
25. de Jonge MI, Vidarsson G, van Dijken HH, Hoogerhout P, van Alphen L, et al.
(2003) Functional activity of antibodies against the recombinant OpaJ protein
from Neisseria meningitidis. Infect Immun 71: 2331–2340.
26. Boulton IC, Gray-Owen SD (2002) Neisserial binding to CEACAM1 arrests the
activation and proliferation of CD4+ T lymphocytes. Nat Immunol 3: 229–236.
27. Pantelic M, Kim YJ, Bolland S, Chen I, Shively J, et al. (2005) Neisseria gonorrhoeae
kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-
expressing human B cells and inhibits antibody production. Infect Immun 73:
4171–4179.
28. de Jonge MI, Hamstra HJ, Jiskoot W, Roholl P, Williams NA, et al. (2004)
Intranasal immunisation of mice with liposomes containing recombinant
meningococcal OpaB and OpaJ proteins. Vaccine 22: 4021–4028.
29. Christodoulides M, McGuinness BT, Heckels JE (1993) Immunization with
synthetic peptides containing epitopes of the class 1 outer-membrane protein of
Neisseria meningitidis: production of bactericidal antibodies on immunization with
a cyclic peptide. J Gen Microbiol 139: 1729–1738.
30. Simms AN, Jerse AE (2006) In vivo selection for Neisseria gonorrhoeae opacity
protein expression in the absence of human carcinoembryonic antigen cell
adhesion molecules. Infect Immun 74: 2965–2974.
31. Ram S, Cullinane M, Blom AM, Gulati S, McQuillen DP, et al. (2001) Binding
of C4b-binding protein to porin: a molecular mechanism of serum resistance of
Neisseria gonorrhoeae. J Exp Med 193: 281–295.
32. Jerse AE (1999) Experimental gonococcal genital tract infection and opacity
protein expression in estradiol-treated mice. Infect Immun 67: 5699–5708.
33. Kellogg DS Jr, Peacock WL Jr, Deacon WE, Brown L, Pirkle DI (1963) Neisseria
Gonorrhoeae. I. Virulence Genetically Linked to Clonal Variation. J Bacteriol 85:
1274–1279.
34. de Ree JM, Schwillens P, van den Bosch JF (1986) Monoclonal antibodies for
serotyping the P fimbriae of uropathogenic Escherichia coli. J Clin Microbiol 24:
121–125.
35. Afonina G, Leduc I, Nepluev I, Jeter C, Routh P, et al. (2006) Immunization
with the Haemophilus ducreyi hemoglobin receptor HgbA protects against infection
in the swine model of chancroid. Infect Immun 74: 2224–2232.
36. Garvin LE, Bash MC, Keys C, Warner DM, Ram S, et al. (2008) Phenotypic and
genotypic analyses of Neisseria gonorrhoeae isolates that express frequently recovered
PorB PIA variable region types suggest that certain P1a porin sequences confer
a selective advantage for urogenital tract infection. Infect Immun 76: 3700–3709.
37. Pal S, Theodor I, Peterson EM, de la Maza LM (1997) Monoclonal
immunoglobulin A antibody to the major outer membrane protein of the
Chlamydia trachomatis mouse pneumonitis biovar protects mice against a
chlamydial genital challenge. Vaccine 15: 575–582.
38. Song W, Condron S, Mocca BT, Veit SJ, Hill D, et al. (2008) Local and humoral
immune responses against primary and repeat Neisseria gonorrhoeae genital tract
infections of 17beta-estradiol-treated mice. Vaccine.
39. Ngampasutadol J, Ram S, Blom AM, Jarva H, Jerse AE, et al. (2005) Human
C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in
species-specific infection. Proc Natl Acad Sci U S A 102: 17142–17147.
40. Villullas S, Hill DJ, Sessions RB, Rea J, Virji M (2007) Mutational analysis of
human CEACAM1: the potential of receptor polymorphism in increasing host
susceptibility to bacterial infection. Cell Microbiol 9: 329–346.
41. Parr EL, Parr MB (1997) Immunoglobulin G is the main protective antibody in
mouse vaginal secretions after vaginal immunization with attenuated herpes
simplex virus type 2. J Virol 71: 8109–8115.
42. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of
virus transmission to macaque monkeys by a vaginally applied monoclonal
antibody to HIV-1 gp120. Nat Med 9: 343–346.
43. Whaley KJ, Zeitlin L, Barratt RA, Hoen TE, Cone RA (1994) Passive
immunization of the vagina protects mice against vaginal transmission of genital
herpes infections. J Infect Dis 169: 647–649.
44. Ram S, Mackinnon FG, Gulati S, McQuillen DP, Vogel U, et al. (1999) The
contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B
Neisseria meningitidis. Mol Immunol 36: 915–928.
45. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, et al. (2008) Human factor
H interacts selectively with Neisseria gonorrhoeae and results in species-specific
complement evasion. J Immunol 180: 3426–3435.
46. Bos MP, Kao D, Hogan DM, Grant CC, Belland RJ (2002) Carcinoembryonic
antigen family receptor recognition by gonococcal Opa proteins requires distinct
combinationsofhypervariable Opaproteindomains.InfectImmun 70:1715–1723.
47. Harvey HA, Jennings MP, Campbell CA, Williams R, Apicella MA (2001)
Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human
urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol
Microbiol 42: 659–672.
48. Han E, Phan D, Lo P, Poy MN, Behringer R, et al. (2001) Differences in tissue-
specific and embryonic expression of mouse Ceacam1 and Ceacam2 genes.
Biochem J 355: 417–423.
49. Bos MP, Hogan D, Belland RJ (1997) Selection of Opa+ Neisseria gonorrhoeae by
limited availability of normal human serum. Infect Immun 65: 645–650.
50. Sherwood JK, Zeitlin L, Chen X, Whaley KJ, Cone RA, et al. (1996) Residence
half-life of IgG administered topically to the mouse vagina. Biol Reprod 54:
264–269.
Opa-Specific Antibody Function
PLoS ONE | www.plosone.org 11 December 2009 | Volume 4 | Issue 12 | e8108